Epithelioid Sarcoma of the Right Forearm With Pulmonary Metastases and Suspected Cardiac Involvement: A Case Report
This case report details the aggressive clinical course of a 35-year-old man with epithelioid sarcoma of the right forearm who underwent amputation and chemotherapy, subsequently developing pulmonary and suspected cardiac metastases that demonstrated discordant responses to targeted therapies before resulting in the patient's death.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is a disease of uncontrolled growth, but not all cancers behave the same way. Some grow slowly and stay in one place, while others are aggressive, spreading quickly to distant parts of the body. Among the rarest and most difficult to treat are soft tissue sarcomas, a group of cancers that develop in the muscles, fat, and connective tissues. A specific type called epithelioid sarcoma is particularly tricky. It often appears in the hands or forearms of young adults as a small, painless lump that seems harmless at first. However, this deceptive appearance can hide a tumor that is prone to returning after surgery and spreading to the lungs or other organs. Doctors rely on a combination of visual clues under a microscope and specific protein markers to identify these tumors. One of the most important markers is a protein called INI1; when a tumor lacks this protein, it confirms a diagnosis of epithelioid sarcoma and points toward a specific biological mechanism that researchers are trying to target with new drugs. Understanding how these tumors move through the body and how they respond to treatment is vital, because the standard approaches often fail to stop them completely.
This story begins with a thirty-five-year-old man who noticed a small, firm lump on the palm side of his right forearm in September 2023. The mass was about the size of a peanut and did not hurt, but it slowly grew over the next five months. When doctors examined him, they saw swelling but no redness or open sores. An MRI scan showed a mass measuring roughly 3.0 by 1.8 centimeters, and a full-body scan showed no signs that the cancer had spread elsewhere. In February 2024, a needle biopsy suggested it was a soft tissue sarcoma. The medical team started a standard chemotherapy regimen using two drugs, doxorubicin and ifosfamide, hoping to shrink the tumor before surgery. However, follow-up scans showed the tumor was actually getting larger and had wrapped itself around critical nerves, blood vessels, and tendons. Because the cancer had encased these vital structures, saving the arm was no longer possible. On April 29, 2024, the patient underwent an amputation of his right upper limb to remove the tumor.
The tissue removed during surgery provided the definitive answers. Under the microscope, the tumor cells showed a mix of shapes, some round and some long, with a central area of dead tissue that looked like a granuloma, a pattern typical of this specific cancer. Tests confirmed the cells lacked the INI1 protein, which solidified the diagnosis of epithelioid sarcoma. The patient received four more cycles of chemotherapy after the surgery to try to catch any remaining microscopic cells. For a time, he seemed to be doing well, but in December 2024, a routine chest scan revealed a new problem. The scan showed multiple new spots in the lungs, indicating the cancer had returned and spread. Even more concerning, the scan revealed a mass inside the heart that looked like it might be another metastasis. Because the patient and his family declined a biopsy of the heart mass, doctors could not confirm with certainty that it was cancer, but the timing and appearance made it highly suspicious.
With the cancer spreading, the medical team turned to a targeted therapy called tazemetostat. This drug works by blocking a specific enzyme that the cancer cells rely on because they lack the INI1 protein. The hope was that this treatment would stop the cancer from growing. By June 2025, the results were mixed. The spots in the lungs remained relatively stable, showing no significant growth, but the mass in the heart had gotten larger. This difference in behavior between the two sites was puzzling. The doctors recommended radiation for the heart mass, but this was also declined. The treatment was switched to a different drug called anlotinib, but the disease continued to progress. The patient passed away at home in early August 2025.
This case highlights several difficult realities about treating this rare cancer. First, it shows how quickly a tumor that seems localized can develop into a widespread disease, even after aggressive surgery and chemotherapy. Second, it illustrates the challenge of treating metastatic cancer when different parts of the body respond differently to the same medicine. In this patient, the lungs held steady while the heart mass grew, suggesting that the cancer cells in different locations may have developed unique traits or that the drug could not reach the heart effectively. The medical team also noted that while the heart mass was highly suspected to be cancer, the lack of a biopsy meant they could not be absolutely sure, leaving some uncertainty about the exact nature of that specific growth.
The report also touches on the changing landscape of cancer treatment. The drug used in this case, tazemetostat, was a logical choice based on the patient's specific genetic profile at the time. However, the authors note that regulatory decisions regarding this drug have since changed due to new safety concerns, meaning this treatment path is no longer the standard recommendation. This underscores the difficulty of managing rare diseases where options are limited and evolve rapidly. The case serves as a reminder that even with modern tools to identify the genetic makeup of a tumor, doctors still face significant hurdles in controlling the spread of the disease, especially when it involves complex organs like the heart. The story of this patient emphasizes the need for better ways to understand how cancer spreads and how to treat different parts of the body when they react in unexpected ways.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.